O-082 15-year-experience in oncological fertility preservation: Impact on disease survival and reproductive outcomes

Abstract Study question What is the impact of fertility preservation (FP) procedures and cancer treatment on relapse, survival, ovarian damage pregnancy outcomes in oncological patients? Summary answer FP technique (including stimulation for oocyte vitrification) does not affect relapse or survival rates even hormone dependant tumours. known already has become a crucial part evaluation young women facing given high achieved. Oocyte vitrification (OV) cortex cryopreservation (OCC) are main techniques offered to these patients at moment. However, information true incidence premature insufficiency (POI), return use cryopreserved material natural achieved still limited. Moreover although there some data about safety disease yet be definitely assessed. design, size, duration Prospective cohort study. 695 enrolled since 2001 until 2016. Patients referred unit public hospital setting (Hospital Peset Valencia 2001-2006 University Hospital La Fe 2007-2016). After 556 received (OV, OCC embryo ) 139 did receive any due medical reasons patient’s choice. Minimum follow-up 5 years after enrolment Participants/materials, setting, methods Baseline characteristics including type previous chemotherapy diagnosis prior were recorded followed by risk received, POI poor reserve (POR) occurrence outcomes. Primary outcome was median time months. Secondary included rate, POR incidence, usage clinical live birth (LB) naturally use. Main results role chance There no differences comparing undergoing versus (median 89.67 vs 92.81 months, p = 0.3). that used their survived more than those who (97.3 89.5, 0.012). When assessing had approval get pregnant we found higher former (98.84 84.79 < 0.001). Breast with dependent tumors OV (95.62 87.38 0.37). 20.29% (N 141). significantly older (32.28 29.63, 0.001) high-risk frequently (31.74% 2.27%, Ovarian also POR) 48.06% 334). Eighty-six (15.47%) material. Among wish 266) 84 spontaneous births (31.58%). conceived younger (30.71 33.46, low-risk (43.20% 23.52%, 0.018). 37 LB (37/86, 43.02%). percentile achieving LBR (OR 1.016, 1.005-1.027, 0.004) Limitations, caution The using mediated prognosis itself limits stable disease. Wider implications findings have negative if used. Almost half (POI as result treatment; this previously reported. around one third naturally. Trial registration number applicable